A Softer Touch: How WISE’s €30M Bet on Flexible Implants Could Remake Pain Care

MILAN, Italy – June 17, 2026 – In a move that signals growing confidence in a new class of medical hardware, Italian neurotechnology firm WISE S.p.A. has closed an oversubscribed €30 million Series D financing round. The capital is earmarked to propel a novel device for chronic pain through the demanding gauntlet of clinical trials and regulatory approval, while also scaling the company's unique platform of soft, stretchable electrodes. This infusion of strategic capital isn't just a win for one company; it’s a powerful validation of a technological shift that could redefine how we interface with the human nervous system.

The round attracted a formidable syndicate of new and existing investors, including a strategic partnership with ENEA Tech and Biomedical, an Italian foundation dedicated to bolstering the nation's life sciences sector. This builds on a previous closing that included a venture debt facility from the European Investment Bank (EIB) and an equity investment from Wallaby S.p.A., the family office behind the industrial giant GVS S.p.A. For patients and physicians, this convergence of public, private, and industrial capital brings a promising new tool one step closer to reality.

A New Paradigm for Chronic Pain

The primary focus of the new funding is the Heron® lead, WISE’s flagship product for Spinal Cord Stimulation (SCS). SCS is a well-established therapy for chronic pain where electrical impulses are used to mask pain signals before they reach the brain. However, the technology has long presented clinicians with a difficult trade-off. Surgical “paddle” leads offer precise, directional stimulation but require an invasive operation to place. Conversely, cylindrical “percutaneous” leads can be implanted with a needle in a minimally invasive procedure but are often less precise and more prone to migrating, which can diminish their therapeutic effect over time.

WISE aims to dissolve this compromise. The Heron® lead is engineered to be the first device that delivers the targeted, directional stimulation of a paddle lead via a minimally invasive percutaneous technique. According to the company, this “dual advantage” could lead to better anatomical coverage, higher energy efficiency, and more stable, long-term results. In a multi-billion-euro market dominated by giants like Medtronic, Boston Scientific, and Abbott, such a breakthrough could represent a significant disruption.

“The oversubscription of this Series D round is a testament to the strength of what our team has built,” said Luca Ravagnan, Chief Executive Officer of WISE. “With the Heron® lead, we are targeting a multi-billion-euro market with a product that addresses a long-lasting unmet clinical need. This financing gives us the resources to complete the journey from bench to bedside.”

That journey, however, is a marathon. As an implantable Class III medical device, the Heron® lead faces the highest level of regulatory scrutiny. The funds will support a critical “first-in-human” study, the initial step in a clinical pathway that, under both the EU’s stringent Medical Device Regulation (MDR) and the FDA’s Premarket Approval (PMA) process in the US, can take many years to complete. Success is not guaranteed, but the secured funding provides the necessary runway to pursue it.

The Foundation: A Stretchable, Bio-Integrated Future

Behind the Heron® lead is WISE’s foundational Supersonic Technology. This proprietary manufacturing process creates electronic circuits integrated into ultra-thin, soft, and stretchable elastomeric foils. Where traditional neural implants are rigid, WISE’s devices are designed to conform to the soft, dynamic tissues of the brain and spinal cord. This superior conformability is not merely an elegant engineering feat; it’s critical to improving safety and efficacy by minimizing tissue inflammation and ensuring a more stable, higher-fidelity connection with neural structures.

This technology is already proven in the market. The WISE Cortical Strip (WCS®), a soft, stretchable grid of electrodes for monitoring brain activity during neurosurgery, has already achieved both CE mark certification under the new MDR and FDA clearance. This makes it the first device of its kind to clear these high regulatory bars, demonstrating the company’s ability to bring this novel technology from concept to clinical use. The new funding will also help expand the commercial footprint of the WCS® in Europe, the USA, and Australia, providing a revenue stream and further validation as the Heron® lead advances.

The broader implications of this platform technology extend far beyond its current applications. The ability to create soft, high-performance bio-integrated electronics is a key enabling step for the next generation of neuromodulation, neuro-monitoring, and the burgeoning field of Brain-Computer Interfaces (BCI).

Strategic Capital and a Vote of Confidence

The composition of WISE's investors tells a story about the changing landscape of European and Italian technology. The involvement of ENEA Tech and Biomedical, a foundation backed by the Italian government, highlights a national strategy to cultivate homegrown leaders in high-tech sectors. It represents a deliberate effort to translate cutting-edge science into industrial and economic strength.

Similarly, the support from the European Investment Bank through its InvestEU program frames WISE’s mission within a continent-wide push for innovation and technological sovereignty. By providing venture debt, the EIB helps de-risk the project for equity investors and ensures that promising but capital-intensive projects have the long-term backing they need. The participation of Wallaby S.p.A., representing the deep industrial expertise of the Scagliarini family, adds a layer of commercial and manufacturing acumen, bridging the gap between a brilliant prototype and a globally scalable product.

Fortifying Governance for Global Ambition

To navigate this next phase of growth, WISE has also strengthened its leadership. The appointment of Laura Iris Ferro as Chairperson brings a titan of the Italian biotech scene to the helm. As the founder of Gentium, a company she took to a Nasdaq listing before its acquisition for approximately $1 billion, Ferro has a clear track record of scaling innovative life science companies for the global stage. Her presence signals serious commercial ambition.

“WISE represents a compelling convergence of advanced materials science, neuroscience, and clinical innovation,” commented Laura Iris Ferro, WISE's new Chairperson. “I am proud to help the company scale its technology and bring high-impact solutions to patients with neurological conditions and chronic pain.”

This move, coupled with the addition of Giuseppe Corvino to the Board of Directors, equips the company with the governance and strategic oversight required for the immense challenges ahead: managing complex international clinical trials, executing a multi-product commercial strategy, and ultimately delivering on the promise of its technology for patients worldwide.